Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Edwards Lifesciences Corporation (NYSE: EW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a structural heart medical device manufacturer. These filings, sourced from the SEC’s EDGAR system, include current reports on material events, earnings announcements, capital markets activity and other items relevant to shareholders and analysts.
Edwards Lifesciences uses Form 8‑K to report developments such as quarterly financial results, financial guidance updates, leadership transitions, accelerated share repurchase agreements and legal or regulatory matters. Recent 8‑K filings, for example, describe third‑quarter financial results, a planned chief financial officer transition, an accelerated share repurchase agreement and legal proceedings related to the Federal Trade Commission’s successful motion to block the proposed acquisition of JenaValve Technology.
In addition to current reports, investors typically review Edwards’ annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which provide detailed information on its structural heart portfolio, risk factors, research and development spending, and segment performance across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies and surgical heart valves. Proxy statements on Schedule 14A and beneficial ownership or insider trading reports on Forms 3, 4 and 5 offer further insight into governance and executive equity activity.
Stock Titan enhances these filings with AI‑powered summaries that explain key points in accessible language, highlight important changes from prior periods and help readers interpret complex sections. Real‑time updates ensure that new Edwards Lifesciences filings appear promptly, while AI‑generated overviews of 10‑K, 10‑Q and Form 4 documents can assist users in quickly understanding the implications of lengthy disclosures and insider transactions without replacing their own review of the original filings.
Edwards Lifesciences Corporation insider filed a Form 144 notice for a planned sale of common stock. The filing covers up to 583 shares of common stock to be sold through Charles Schwab & Co., Inc. on or about 12/08/2025 on the NYSE, with an aggregate market value of $50,144.00. The issuer has 580,300,000 shares of common stock outstanding.
The shares to be sold were acquired through equity compensation, specifically restricted stock lapses of 316 shares on 09/14/2024 and 267 shares on 09/14/2025 from Edwards Lifesciences Corporation. The seller represents that they are not aware of any material adverse, nonpublic information about the company’s operations.
Edwards Lifesciences Corporation (EW) has a shareholder filing a notice to sell 21,487 shares of its common stock under Rule 144. The shares are to be sold through broker Charles Schwab & Co., Inc. on the NYSE, with an aggregate market value of $1,831,006 and 580,300,000 common shares stated as outstanding. The seller acquired these shares on 12/08/2025 through an employee stock option exercise, using a broker payment for a cashless exercise on the same date. The person signing the notice represents that they are not aware of any undisclosed material adverse information about Edwards Lifesciences’ current or prospective operations.
Edwards Lifesciences (EW) reported an insider equity grant. The company’s SVP, Corporate Controller, acquired 1,160 shares of common stock at $0.0000 on 11/13/2025.
The filing explains these restricted stock units were granted under the Long‑Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Following the transaction, the officer’s beneficial ownership was 9,183.074 shares, held directly. The filing also notes quarterly acquisitions under the Employee Stock Purchase Plan.
Edwards Lifesciences (EW): Form 144 filed for a proposed sale. Larry L. Wood filed a notice to sell 26,850 shares of Edwards Lifesciences common stock, with an aggregate market value of $2,285,355.00. The approximate sale date is 11/11/2025, via Charles Schwab & Co., Inc. on the NYSE.
The shares to be sold were acquired on 11/11/2025 through an employee stock option exercise with a broker payment for cashless exercise. In the past three months, the filer sold 8,950 shares on 08/18/2025 for $698,679.00 and 8,950 shares on 10/16/2025 for $653,522.00. Shares outstanding were 580,300,000; this is a baseline figure, not the amount being sold.
Edwards Lifesciences (EW) reported insider activity by its Chief Financial Officer. On 11/10/2025, the officer exercised employee stock options for 13,000 shares of common stock at an exercise price of $59.2567 per share and executed sales on the same date pursuant to a Rule 10b5-1 trading plan adopted on July 29, 2025.
The transactions included two sales: 2,974 shares at a weighted average price of $83.2999 (trades ranged from $83.270 to $83.415) and 10,026 shares at a weighted average price of $83.0201 (trades ranged from $82.270 to $83.260). Following these transactions, direct beneficial ownership stood at 39,898 shares, with an additional 266,318 shares held indirectly by trust. After the option exercise, 46,700 derivative securities (stock options) remained beneficially owned.
Edwards Lifesciences (EW) reported an insider Form 4 for an officer (CVP, JAPAC) on 11/10/2025. The reporting person exercised 1,020 employee stock options at $59.2567 and sold 1,020 common shares at a weighted average price of $82.5451, with trades ranging from $82.27 to $82.90. These transactions were made under a Rule 10b5-1 trading plan adopted on July 30, 2025. After the transactions, direct ownership was 22,001.9103 shares, and 6,114 derivative securities remained held directly.
Edwards Lifesciences (EW) filed a Form 144 for a proposed sale of 3,058 shares of common stock through Charles Schwab & Co., Inc. on 11/10/2025. The aggregate market value listed is $252,423, with sales on the NYSE. The shares were acquired the same day via an employee stock option exercise with broker payment for a cashless exercise. Shares outstanding were 580,300,000; this is a baseline figure, not the amount being sold.
Edwards Lifesciences (EW) reported a planned sale under Form 144. The notice covers up to 20,700 common shares with an aggregate market value of $1,719,841.00, to be executed through Charles Schwab on or about 11/10/2025 on the NYSE. The seller acquired the shares via an employee stock option exercise with a broker payment for cashless exercise on the same date. Shares outstanding were 580,300,000 at the time cited.
Edwards Lifesciences (EW) reported Q3 2025 results. Net sales rose to $1,553.1M from $1,354.4M, while operating income declined to $307.1M from $350.6M as expenses increased. Diluted EPS from continuing operations was $0.50 versus $0.61 a year ago. Total diluted EPS was $0.50, compared with $5.13 last year, which included a large discontinued operations gain.
The quarter included $90.4M of certain litigation expenses and a $40.0M intangible asset impairment, partially offset by a $12.5M favorable change in contingent consideration and $12.5M of other operating income. Year-to-date cash from operations improved to $1,144.3M. Cash, cash equivalents, and restricted cash were $2,694.8M at period end.
Following the 2024 sale of Critical Care, discontinued operations posted a small loss this quarter. Edwards recorded TSA income of $12.7M and reported a remaining unfavorable contract liability of $47.1M tied to services, with a net payable to BD of approximately $84.4M. The company repurchased $852.8M of stock year-to-date and acquired the remaining interest in Vectorious for $233.7M. Shares outstanding were 580.3 million as of October 31, 2025.
Edwards Lifesciences announced a planned leadership change as Chief Financial Officer Scott Ullem informed the company he will transition from his role by mid-year 2026.
The company has begun a selection process to appoint a new CFO. A press release announcing the transition plan was issued on October 30, 2025 and furnished under Item 7.01; it is not deemed “filed” under the Exchange Act.
Edwards Lifesciences announced a planned leadership change as Chief Financial Officer Scott Ullem informed the company he will transition from his role by mid-year 2026.
The company has begun a selection process to appoint a new CFO. A press release announcing the transition plan was issued on October 30, 2025 and furnished under Item 7.01; it is not deemed “filed” under the Exchange Act.